Flumatinib
As of the edition of 20 October 2026, Flumatinib is a small molecule: stopped in 2023; acts on ABL1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2023
- Kind
- Small molecule
- Registered trials
- 11, 1 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ABL1 | Tyrosine-protein kinase ABL1 | P00519 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 0 | 0 |
| Phase 2 | 3 | 1 | 0 | 0 |
| Phase 3 | 2 | 1 | 0 | 0 |
| Phase 4 | 4 | 0 | 1 | 1 |
| All trials | 11 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Jiangsu HengRui Medicine | Lead sponsor of trials | 2011 to now |
| Jiangsu Hansoh Pharmaceutical | Lead sponsor of trials | 2013 to now |